Neuroscience Is Taking the Spotlight at ’s Bay Area Xchange
Summary
The South San Francisco biotech is developing antibody therapies that bolster immune cells that help the brain clear away proteins and debris associated with neurodegenerative disorders. BlackThorn Therapeutics is deploying technologies such as artificial intelligence and brain imaging that help it discover new drugs and enroll the clinical trials to test them. At our forum, Jane Tiller, BlackThorn’s chief medical officer, and Kristina Burow of ARCH Venture Partners, will tell BlackThorn’s story from its Scripps origins to the present day as a clinical-stage company backed by $116 million in financing. Ethan Perlstein, the Reeve Foundation’s chief scientific officer, will talk about the foundation’s efforts to find new treatments and potential cures for spinal cord injury. If you’d like to hear more about these new efforts to treat brain disorders and spinal cord injury, join us at the Hyatt Regency San Francisco for What’s Next in Neuroscience Therapies.
Classifications
AskAI Classifications
LabelsLinked Companies
